Terns Pharmaceuticals, Inc. Board of Directors

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Mr. David Eric Strauss

Mr. David Eric Strauss

VP of Finance & Controller

Ms. Debra Sieminski

Ms. Debra Sieminski

Senior Vice President of Medical Affairs

Ms. Melita Sun Jung

Ms. Melita Sun Jung

Chief Business Officer

Mr. Scott Harris

Mr. Scott Harris

Chief Development Officer

Dr. Jeffrey R. Jasper Ph.D.

Dr. Jeffrey R. Jasper Ph.D.

Senior Vice President of Research

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.